Latest American College of Rheumatology Stories
Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a Phase IIIb study in adult patients with early moderate-to-severe erosive rheumatoid arthritis (RA) who had never received previous methotrexate (MTX) treatment.
SAN FRANCISCO, Oct.
Incyte Corporation (Nasdaq:INCY) announced today the presentation of clinical results from a 28-day Phase IIa trial of INCB18424, its orally available janus kinase (JAK) inhibitor, in patients with rheumatoid arthritis (RA).
NUTLEY, N.J., Oct. 25 /PRNewswire/ -- One-year data from a two-year Phase III study demonstrated that ACTEMRA(R) (tocilizumab) significantly inhibited the progression of structural joint damage in patients with rheumatoid arthritis (RA).
NUTLEY, N.J., Oct.
Pacific Biometrics, Inc.
Pfizer will highlight several presentations and posters across a spectrum of pain and inflammatory conditions at the American College of Rheumatology (ACR) annual meeting in San Francisco from October 25 to 29, 2008.
D2Hawkeye(R), Inc., the market leader in transforming healthcare data into valuable information for managing clinical risk and costs, announced today that Michael Kane, M.D., D2Hawkeye Consultant, will be presenting at the American College of Rheumatology/Association of Rheumatology Health Professionals Scientific Meeting 08, on October 24-29, 2008 in San Francisco, CA.
- A serpent whose bite was fabled to produce intense thirst.